(PRWEB) January 21, 2015
Los Angeles, California: The collaboration is for the production of Vault Nano’s lead cancer drug, VNI-101. VNI-101 is a cytokine-based immune stimulant that is delivered by a novel human protein nanoparticle, called a vault. Discovered at UCLA, vaults are being commercialized for a number of therapeutic indications by VNI. VNI-101 will be initially tested in patients with stage IV lung cancer and will ultimately be applied to melanoma and other metastatic cancers. The drug will be the cornerstone of multiple anti-cancer immune therapies being developed by the company that promise to be highly effective while reducing the long-term toxicity of today’s chemotherapeutics.
The manufacturing collaboration will focus on:
1. Producing the human vault therapeutic, VNI-101, according to Good Laboratory Practices (GLP) to be used for toxicology studies,
2. Scaling up manufacturing of VNI-101 sufficient to provide material for safety and efficacy clinical trials, and
3. Producing clinical Good Manufacturing Practices (cGMP) VNI-101 for human clinical trials.
“VNI-101 is Vault Nano’s premiere drug in the immune oncology space, and this collaboration will enable VNI to leapfrog several years of manufacturing development and enter clinical trials by next year,” said Michael Laznicka, VNI Chairman and CEO. “Protein Sciences with their FDA approved protein manufacturing systems will be an ideal partner for our company.”
About Vault Nano Inc.
Vault Nano Inc., located in Los Angeles, California, is the leading biotechnology company in developing, and commercializing Vault Medicines. VNI’s mission is to develop safe and effective immunotherapeutics with the goal of changing the existing treatment paradigm of life-threatening and debilitating diseases.
About Protein Sciences
Protein Sciences Corporation, headquartered in Meriden, CT, specializes in vaccine development and protein production. PSC’s mission is to save lives and improve health through the creation of innovative vaccines and biopharmaceuticals. Protein Sciences developed, manufactures and offers for sale Flublok®, the world’s first recombinant protein-based vaccine for the prevention of seasonal influenza disease. Flublok was approved by FDA in January 2013. Flublok is the only flu vaccine made in a 100% egg-free system using modern cell culture technology. Flublok is highly purified and does not contain any preservatives, egg proteins, gelatin or latex.